Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025

Core Insights - Abpro Holdings, Inc. has implemented a 1-for-30 reverse stock split to maintain compliance with Nasdaq and position the company for future growth [1][4] - The company has achieved approximately 60% reduction in operating costs compared to the same period in 2024 through a focused cost optimization plan [1][4] - Abpro's partnership with Celltrion is a strategic advantage, as Celltrion funds all development expenses for Abpro's lead antibody program ABP-102, with a first-in-human trial anticipated in 2026 [5][4] Company Actions - The reverse stock split became effective on October 31, 2025, reducing the number of outstanding shares from approximately 81.2 million to 2.7 million [2] - The company's transfer agent, Continental Stock Transfer & Trust Company, will act as the exchange agent for the reverse stock split [3] Strategic Positioning - Abpro is focused on unlocking additional value through its DiversImmune® and MultiMabTM platforms, which facilitate the rapid creation of bispecific and multispecific antibodies [6] - The company aims to create long-term value for shareholders by executing more effectively with a leaner cost structure and a major global partner [4] Company Overview - Abpro is dedicated to improving lives through next-generation antibody therapies targeting severe diseases, utilizing its proprietary DiversImmune® platform [7]